The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis
Open accessAbstract
Previous in vivo studies have characterized the pharmacodynamic characteristics of two triazole compounds, fluconazole and ravuconazole. These investigations demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic-pharmacodynamic (PK-PD) parameter associated with treatment efficacy. Further analysis demonstrated that a free-drug triazole 24-h AUC/MIC ratio of 20 to 25 was predictive of treatment success in both experimental models and clinical trials. We used a neutropenic murine model of disseminated Candida albicans infection to similarly characterize the time course activity of the new triazole, posaconazole. The PK-PD parameters (percent time above MIC, AUC/MIC ratio, and peak serum drug level/MIC ratio) were correlated with in vivo efficacy, as measured by organism number in kidney cultures after 48 h of therapy. Kinetics and protein binding following oral posaconazole dosing were performed in neutropenic infected mice. Peak levels and AUC from 0 h to ∞ values were nonlinear over the 16-fold dose range studied. Serum drug elimination half-life ranged from 12.0 to 17.7 h. Protein binding was 99%. Single dose postantifungal effect studies demonstrated prolonged suppression of organism regrowth after serum posaconazole levels had fallen below the MIC. Treatment efficacy with the four dosing intervals studied was similar, supporting the AUC/MIC ratio as the PK-PD parameter predictive of efficacy. Nonlinear regression analysis also suggested that the AUC/MIC ratio was strongly predictive of treatment outcomes (AUC/MIC ratio R 2 = 83%; peak serum drug/MIC ratio R 2 = 85%; time that serum levels of posaconazole remained above the MIC R 2 = 65%). Similar studies were conducted with 11 additional C. albicans isolates with various posaconazole susceptibilities (MIC, 0.015 to 0.12 μg/ml) to determine if a similar 24-h AUC/MIC ratio was associated with efficacy. The posaconazole free-drug AUC/MIC ratios were similar for all of the organisms studied (6.12 to 26.7, mean ± SD = 16.9 ± 7.8, P value, 0.42). These free-drug AUC/MIC ratios are similar to those observed for other triazoles in this model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo animal studies against a large number of Candida strains with widely varying MICs (more than 2000-fold) show that the 24-hour AUC/MIC target associated with efficacy (50% maximal effect) for triazoles occurs at a value near 25 when free drug (non-protein bound) levels are considered.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [141]
Experimental — accuracy not yet measuredIn the citing paper
“In addition, in vivo studies have revealed prolonged periods of growth suppression after triazole concentrations decrease to less than the MIC (long PAFE).”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Antibiotics in Laboratory Medicine.
Lorian, V. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,809
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S. R., Leggett, J., Turnidge, J. D., Ebert, S. C., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Dowell, S. F., Butler, J. C., Giebink, G. S., Jacobs, M. R., Jernigan, D. B., Musher, D. M., Rakowsky, A., & Schwartz, B. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199901000-00002 · Cited by 505
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
Craig, W. A., & Andes, D. R. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 438
Self-citationRedding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A. K., Coffman, S. L., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Andes, D. R., & Craig, W. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2375 · Cited by 255
Self-citationKlepser, M. E., Wolfe, E. J., Jones, R. N., Nightingale, C. H., & Pfaller, M. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1392 · Cited by 245
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
Self-citationActivity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo
Rogers, T. E., & Galgiani, J. N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.3.418 · Cited by 185
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
Louie, A., Drusano, G. L., Banerjee, P., Liu, Q.-F., Liu, W., Kaw, P., Shayegani, M., Taber, H., & Miller, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1105 · Cited by 154
INFLUENCE OF BINDING ON THE PHARMACOLOGIC ACTIVITY OF ANTIBIOTICS
Kunin, C. M., Craig, W. A., Kornguth, M. L., & Monson, R. A. (1973) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1973.tb20483.x · Cited by 146
Kunin, C. M. (1966) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196672166 · Cited by 136
Cacciapuoti, A. F., Loebenberg, D., Corcoran, E., Menzel, F., Moss, E. L., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C. A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2017-2022.2000 · Cited by 110
Self-citationIn vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1193-1199.2003 · Cited by 98
Self-citationLee, S.-C., Fung, C., Huang, J., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L., & Wb, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2715-2718.2000 · Cited by 81
Van t Wout, J. W., Mattie, H., & van Furth, R. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.147 · Cited by 72
Reeves, D. S. (1999) · Cited by 65
SCH56592 treatment of murine invasive aspergillosis
Graybill, J. R., Bocanegra, R. A., Najvar, L. K., Luther, M. F., & Loebenberg, D. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.4.539 · Cited by 49
Self-citationRyan, D. M., Hodges, B., Spencer, G. R., & Harding, S. M. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.22.6.995 · Cited by 44
Research works printed but not linked: 2
- Craig W. A. and B. Suh. 1996. Protein binding and the antimicrobial effects: methods for the determination of protein binding p. 367-402. In V. Lorian (ed.) Antibiotics in laboratory medicine 4th ed. Williams and Wilkins Baltimore Md.
- Kunin, C. M. 1965. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin. Pharmacol. Ther.7:168-179.
Cited by
Sorted by citations
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 721
Recent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B. J., Walsh, T. J., Kontoyiannis, D. P., Edwards, J. E., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Self-citationPharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 482
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 452
Metadata
- Authors
- Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D.
- Affiliations
- University of Wisconsin System (US)
- William S. Middleton Memorial Veterans Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-01
- Volume
- 48
- Issue
- 1
- Pages
- 137-142
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC310197
- OpenAlex
- W2126064588
- Cited by
- 177
- References
- 26
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 8 · 2017: 4 · 2016: 5 · 2015: 8 · 2014: 8 · 2013: 12 · 2012: 9
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- posaconazole, triazole antifungals, pharmacodynamics, pharmacokinetics, systemic candidiasis, Candida albicans, AUC/MIC ratio, neutropenic mice, free drug concentration, drug-protein binding, elimination half-life, fluconazole, ravuconazole, treatment efficacy prediction, nonlinear pharmacokinetics
- MeSH terms
- Animals, Antifungal Agents, Candida albicans, Candidiasis, Dose-Response Relationship, Drug, Female, Mice, Inbred ICR, Microbial Sensitivity Tests, Neutropenia, Triazoles, Colony Count, Microbial, Area Under Curve, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review